{"id":559,"date":"2026-10-21T09:44:01","date_gmt":"2026-10-21T13:44:01","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=559"},"modified":"2026-10-21T09:44:03","modified_gmt":"2026-10-21T13:44:03","slug":"when-does-tissue-processing-cross-the-regulatory-line-and-require-pre-market-review","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2026\/10\/21\/when-does-tissue-processing-cross-the-regulatory-line-and-require-pre-market-review\/","title":{"rendered":"When Does Tissue Processing Cross the Regulatory Line and Require Pre-Market Review?"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">By <a href=\"https:\/\/www.duanemorris.com\/attorneys\/frederickrball.html\">Frederick R. Ball<\/a>, <a href=\"https:\/\/www.duanemorris.com\/attorneys\/coleenwhill.html\">Coleen W. Hill<\/a> and <a href=\"https:\/\/www.duanemorris.com\/attorneys\/kelechianyatonwu.html\">Kelechi Anyatonwu<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For developers of human cells, tissues, and cellular and tissue-based products, classification can determine the shape of an entire regulatory strategy and ultimately how to get that product to market. Is a product regulated solely under Section 361 of the Public Health Service Act, or does it require pre-market review as a drug, biological product or medical device? A recent decision out of the U.S. District Court for the Northern District of Georgia, <em>MiMedx Group, Inc. v. FDA<\/em>, offers a timely insight into how courts may scrutinize FDA\u2019s answers to those questions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.duanemorris.com\/alerts\/when_does_tissue_processing_cross_regulatory_line_require_premarket_review_1026.html\">Read the full <em>Alert<\/em> on the Duane Morris LLP website<\/a>. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By Frederick R. Ball, Coleen W. Hill and Kelechi Anyatonwu For developers of human cells, tissues, and cellular and tissue-based products, classification can determine the shape of an entire regulatory strategy and ultimately how to get that product to market. Is a product regulated solely under Section 361 of the Public Health Service Act, or &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2026\/10\/21\/when-does-tissue-processing-cross-the-regulatory-line-and-require-pre-market-review\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;When Does Tissue Processing Cross the Regulatory Line and Require Pre-Market Review?&#8221;<\/span><\/a><\/p>\n","protected":false},"author":33,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[605,29,209,737],"ppma_author":[527],"class_list":["post-559","post","type-post","status-publish","format-standard","hentry","category-general","tag-coleen-hill","tag-fda","tag-frederick-ball","tag-kelechi-anyatonwu"],"authors":[{"term_id":527,"user_id":33,"is_guest":0,"slug":"frball","display_name":"Frederick R. Ball","avatar_url":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-content\/uploads\/sites\/15\/2018\/10\/ballfrederick-125x150.jpg","author_category":"","last_name":"Ball","first_name":"Frederick R.","job_title":"","user_url":"http:\/\/www.duanemorris.com\/attorneys\/frederickrball.html","description":"<a href=\"http:\/\/www.duanemorris.com\/attorneys\/frederickrball.html\">Read Frederick's bio.<\/a>"}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=559"}],"version-history":[{"count":1,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/559\/revisions"}],"predecessor-version":[{"id":560,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/559\/revisions\/560"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=559"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}